Valeant Pharmaceuticals International (VRX) to Partner with ASCEND Therapeutics, Inc. to Promote Migranal(R) to OB/GYNs  
10/2/2007 11:01:51 AM

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Valeant Pharmaceuticals International (NYSE:VRX) today announced that it has granted ASCEND Therapeutics exclusive rights to deploy ASCEND’s 50-person specialty sales force to promote Valeant’s Migranal® (dihydroergotamine mesylate, USP) Nasal Spray to more than 5,500 OB/GYNs in the United States. Valeant will continue to market Migranal to physicians outside the OB/GYN specialty area and retain all other responsibilities for the product.